IMVT241115C17000
- 0.00
- 0.000.00%
Immunovant Newsroom
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $48 to $58
Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Immunovant's Promising Pipeline and Strategic Advancements Justify Buy Rating
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Promising Phase 2a Results for Immunovant's Batoclimab Support Buy Rating
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Raymond James Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $36
Raymond James Reinstates Outperform on Immunovant, Announces $36 Price Target
Immunovant Is Maintained at Outperform by Oppenheimer
Immunovant Analyst Ratings
Oppenheimer Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $57
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $44 to $60
Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Immunovant Amid Promising IMVT-1402 Clinical Trial Results for Graves' Disease
Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained
Immunovant Analyst Ratings